{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"0.0"},{"groupId":"OG007","value":"0.0"},{"groupId":"OG008","value":"1.7"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"10.0"},{"groupId":"OG005","value":"7.7"},{"groupId":"OG006","value":"0.0"},{"groupId":"OG007","value":"1.4"},{"groupId":"OG008","value":"9.3"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"16.7"},{"groupId":"OG003","value":"33.3"},{"groupId":"OG004","value":"10.0"},{"groupId":"OG005","value":"38.5"},{"groupId":"OG006","value":"20.0"},{"groupId":"OG007","value":"30.1"},{"groupId":"OG008","value":"36.4"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"85.7"},{"groupId":"OG002","value":"83.3"},{"groupId":"OG003","value":"66.7"},{"groupId":"OG004","value":"70.0"},{"groupId":"OG005","value":"46.2"},{"groupId":"OG006","value":"80.0"},{"groupId":"OG007","value":"50.7"},{"groupId":"OG008","value":"44.9"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"14.3"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"0.0"},{"groupId":"OG007","value":"4.1"},{"groupId":"OG008","value":"4.2"}]}],"title":"Not Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"0.0"},{"groupId":"OG007","value":"0.0"},{"groupId":"OG008","value":"0.0"}]}],"title":"Not Assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"10.0"},{"groupId":"OG005","value":"7.7"},{"groupId":"OG006","value":"0.0"},{"groupId":"OG007","value":"13.7"},{"groupId":"OG008","value":"3.4"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"73"},{"groupId":"OG008","value":"118"}],"units":"Participants"}],"description":"BOR was evaluated per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Stable disease (SD): no change in target lesions to qualify for CR, PR, or progressive disease (PD). PD: progression of a target or non-target lesion or presence of a new lesion. Missing: participant had a missing BOR because there were no post-Baseline tumor assessments. Pleural mesothelioma was evaluated using modified RECIST criteria.","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"},{"description":"INCB001158 was administered orally at 50 mg BID in combination with pembrolizumab at 200 mg intravenously (IV) every 3 weeks (Q3W).","id":"OG004","title":"Part 1B: INCB001158 50 mg + Pembrolizumab"},{"description":"INCB001158 was administered orally at 75 mg BID in combination with pembrolizumab at 200 mg IV Q3W.","id":"OG005","title":"Part 1B: INCB001158 75 mg + Pembrolizumab"},{"description":"INCB001158 was administered orally at 100 mg BID in combination with pembrolizumab at 200 mg IV Q3W.","id":"OG006","title":"Part 1B: INCB001158 100 mg + Pembrolizumab"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG007","title":"Part 2: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 100 mg BID (50 mg BID for Part 1c renally impaired participants) in combination with pembrolizumab at 200 mg IV Q3W.","id":"OG008","title":"Part 1c and Part 3: INCB001158 100 mg + Pembrolizumab"}],"paramType":"NUMBER","populationDescription":"REEP. Participants enrolled in Part 1c had renal impairment. These participants received INCB001158 50 mg + pembrolizumab, which was half the recommended Phase 2 dose of INCB001158. It was pre-specified to combine Part 1c and Part 3 participants for efficacy analysis based on planned comparable dosing according to renal function. Two participants evaluable for PFS were not evaluable for response.","reportingStatus":"POSTED","timeFrame":"Until disease progression/study discontinuation (up to approximately 5 years)","title":"Percentage of Participants With the Indicated Best Overall Response (BOR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}